In this episode of The Dr. Gabrielle Lyon Show, Dr. Lyon sits down with Shalin Shah, CEO of Marius Pharmaceuticals, to explore the science, benefits, and future of testosterone therapy. Shalin has been a driving force behind bringing Kyzatrex, an FDA-approved oral testosterone, to market—making testosterone therapy more accessible and effective for both men and women. From breaking down misconceptions to advocating for better access to hormone therapy, this conversation sheds light on how testosterone plays a crucial role in overall health and wellness.
Shalin shares his journey, discussing how his background in investments and his drive to bring valuable but overlooked health solutions to the mainstream led him to develop Kyzatrex. They dive into the challenges he faced in bringing this groundbreaking therapy to market, and how Marius Pharmaceuticals is striving to change the narrative around testosterone through education and advocacy.
We dive into:
Tune in to hear Shalin’s insights into the future of hormone therapy and the steps his team is taking to improve access and education around testosterone. This episode is a must-listen for anyone interested in health optimization, longevity, or understanding how testosterone therapy can impact overall quality of life.
Who is Shalin Shah?
Shalin Shah is a distinguished leader in the field of metabolic health, specializing in testosterone replacement therapy. As the Chief Executive Officer of Marius Pharmaceuticals, he was instrumental in the development and FDA approval of KYZATREX® (testosterone undecanoate) CIII Capsules, an oral testosterone treatment for adult men with low or no testosterone levels due to certain medical conditions.
With a global investment background, Shalin transitioned into healthcare with a mission to revolutionize the industry through metabolic health. His leadership at Marius Pharmaceuticals is marked by innovative strategies that prioritize consumer access and education. Under his guidance, KYZATREX has been launched via consumer-focused channels that include preeminent national healthcare institutions, private-equity backed medical practices, and national telemedicine platforms.
Shalin’s expertise extends beyond corporate leadership; he is an influential voice in longevity medicine and an advocate for reevaluating testosterone medication regulations. His efforts aim to reshape public perception and education on testosterone therapy and its significance for global health. He believes that oral testosterone replacement therapy has created a much-awaited paradigm shift which is critical for addressing the worldwide men’s (and women’s) health crisis, marked by declining testosterone levels and lower life expectancies. His message is that testosterone replacement therapy is not just about adding years to life, but also about adding life to years.
Read More -...